Priveq – new growth partner of Metenova


Metenova, a MedTech company delivering products and solutions for the pharmaceutical and biotech production of aseptic and sterile products, has chosen to incorporate Priveq Investment (“Priveq”) as a new growth partner for the future. Founder, CEO and Management will continue to be a part of the ownership group to a large proportion.

Metenova was founded ten years ago, consisting of a management and founders with over four decades of experience within product design and development of mixer solutions for aseptic and sterile pharmaceutical production. The customer base is mainly leading pharmaceutical companies and biological drug producing companies. The portfolio consists of mixers adapted to different types of applications based on the company’s patented technologies. Metenova operates globally with sales in more than 30 countries, mainly through a distributor network with headquarters in Mölndal, in the south of Sweden and a subsidiary in New Jersey, USA.

With an increasing proportion of biological pharmaceuticals, a large proportion of traditional pharmaceuticals such as block busters, as well as high growth in the Chinese market as a result of a shift to defined pharmaceuticals, there is a high underlying growth for products and knowledge from Metenova. New potent pharmaceuticals and personalized pharmaceuticals also give increased interest in new products within Metenova’s focus area. Through the partnership with Priveq, good conditions are created for taking advantage of the opportunities that can arise in the market as well as continued growth and development of the company.

”We are impressed by how Metenova has managed to establish itself as a technology leader in a relatively short period of time with a strong offering and a unique position in the market. We know the founders and management since we owned the company NovAseptic together and therefore have great respect for the knowledge that exists and being built in Metenova. We are looking forward to working with the owners and management of Metenova and actively supporting the company in the future.” says Louise Nilsson, CEO and partner at Priveq.

”We are very happy to bring Priveq in as growth partner in Metenova. Priveq has a broad experience from 125 growth companies and we are convinced that Priveq will help us take the next step in our development. In addition, we have previously worked together with Priveq and therefore we look forward to a new journey together with confidence.” says Johan Westman, CEO at Metenova.

“With Priveq as a strong owner, we see great opportunities to continue our planned growth. This gives us a good position to realize the opportunities we see in the market and to carry through the ventures we want in order to reach maximum potential.” says Lennart Myhrberg, one of the founders of Metenova.

 For more information, please contact:

Louise Nilsson, CEO and partner, Priveq Investment
Tel: +46 (0)709 50 95 50

Johan Westman, CEO Metenova
Tel: +46 (0)706 02 41 21


About Metenova

Metenova is a global supplier of critical products and solutions for production of aseptic and sterile pharmaceuticals. The company has a long experience of product development, manufacturing and sales within this area with high regulatory requirements. Metenova operates globally with leading companies within pharmaceutical and biotech industries mainly through a distributor network. The headquarters are located in Mölndal, in the south of Sweden and there is also a subsidiary in New Jersey, USA.

More information is available at


For further information, please contact

Louise Nilsson medarbetare

Louise Nilsson

Partner & CEO

Phone: +46 8 459 67 63
Mobile: +46 70 950 95 50

Read more »

Categories: News


ARDIAN acquires majority stake in NEOPHARMED GENTILI


Investment will establish Del Bono family and Ardian as strategic partners in Italy

Milan, November 28 2018 – Mediolanum Farmaceutici, a pharmaceutical company founded by the Del Bono family and now one of the most prominent players in the Italian cardiovascular market, has selected Ardian, a world-leading private investment house, as its strategic partner to further build its presence in Italy and continue the international growth plan of its subsidiary Neopharmed Gentili.

Under the agreement, Ardian will acquire a majority stake in Neopharmed Gentili, which focuses on therapeutic products. Mediolanum Farmaceutici, which was founded in 1972, will retain a minority stake. Alessandro Del Bono will become Chairman and CEO of the company, which is headquartered in Milan.

Neopharmed Gentili S.p.A. comprises the brands of the Mediolanum Farmaceutici Group, which are all dedicated to the development, production and marketing of high value therapeutic products in the vascular, cardio-metabolic, respiratory, antibiotic and over-the-counter drug markets in Italy.

With a strong, high-quality sales network, combined with sector expertise and well-established industry relationships, Neopharmed Gentili recorded sales of €192 million in 2017. Neopharmed Gentili is a well-recognized pharmaceutical brand in the sector, particularly in several specialized therapeutic areas. It is a reliable, specialized partner of many large pharmaceutical companies, including Merck and Teva for which it distributes and supplies some licensed products.

The acquisitions carried out by Neopharmed Gentili have to date allowed the company to significantly increase its market share, its product range offer and to strengthen its top-line, while expanding its share of proprietary products.

Alessandro Del Bono, Chairman and CEO of Neopharmed Gentili, said: “The aim of Neopharmed Gentili is to become an increasingly competitive player in the pharmaceutical sector, oriented towards growth, international expansion and value creation. We have chosen to share this project with Ardian, the leading private equity player in Europe and the third largest in the world. The deal will allow the company to accelerate its development and to target new acquisitions, strengthening its presence in strategic areas of the pharmaceutical sector, and, last but not least, to protect employment in our country”.

Nicolò Saidelli, Managing Director and Head of Ardian in Italy, added: “We are proud that the Del Bono family has chosen Ardian as their partner for the development of Neopharmed Gentili, which represents an example of Italian entrepreneurial excellence combined with strong growth opportunities. Today Neopharmed Gentili is well-known within the Italian pharmaceutical industry and is ready to begin expanding internationally, through important partnerships with global players such as Merck and Teva Pharmaceutical. We are pleased to support the Del Bono family in this new challenge and we will do it with passion, thanks to the experience and skills that distinguish Ardian and the many development projects already followed in Italy together with entrepreneurs and managers at the head of family businesses.”


Mediolanum Farmaceutici was set up in Milan in 1972. Right from the start, the intention was to create a group operating on the international scene with its own products.
Mediolanum Farmaceutici strongly believes that the creation of value determined by the satisfaction of patients and scientific community’s needs, is possible only if due consideration is given to ethical principles and values. Since 1972, the Company developed four products and over 700 patents for more than 40 nations.
The Group can claim a dynamic and trustworthy image and strongly believes in the Social Responsibility culture in order to grant a service to the community.
For further information:


Neopharmed Gentili is an Italian pharmaceutical group founded in Milan in 2011, after the fusion of two eminent firms, Gentili Srl and Neopharmed Srl, respectively taken over in 2009 and 2010. Today Neopharmed Gentili is one of the most important player in the Italian pharmaceutical market. Over the years, the company expanded its business through partnership and acquisitions, which contributed to develop its product portfolio and strengthen its presence in strategic therapeutic areas. In particular, in 2017, the company took over the Italian branch of the Belgian company Therabel Gienne Pharma and established a partnership with Teva Pharmaceuticals for marketing and development of the portfolio in the respiratory area.
Neopharmed Gentili is focused on the research, development, production and distributions of medicines in many therapeutic areas such as vascular and cardio-metabolic areas, pneumological area, antibiotics, OTCs, and supplements.
For further information:


Ardian is a world-leading private investment house with assets of US$82bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 550 employees working from fourteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo). It manages funds on behalf of around 750 clients through five pillars of investment expertise: Funds of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.
Ardian on Twitter @Ardian


Ardian Advisors
M&A Advisor: Rothschild
Commercial Due Diligence: Bain – Valerio di Filippo
Financial Due Diligence: PWC – Emanuela Pettenò
Tax: Gitti & Partners – Diego De Francesco, Paolo Ferrandi
Legal: Giovannelli e Associati – Alessandro Giovannelli, Fabrizio Scaparro
Financing: Gattai, Minoli, Agostinelli & Partners – Lorenzo Vernetti

M&A Advisor: Four Partners – Guido Tugnoli, Pietro Pagnozzi, Angela Celetti
Legal Advisor: NCTM – Pietro Zanoni


Neopharmed Gentili S.p.A.
Ottavia Landi di Chiavenna
Head of External Relations and Institutional Affairs
+39 06.94354560
Mediolanum Farmaceutici
Value Relations
Angela Del Giudice
Domenica Donato

Categories: News


Ardena acquires Syntagon and strengthens API offering

Mentha Capital

Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.

The acquisition, which is the CDMO’s first outside the Benelux region, expands its drug substance manufacturing capacity. Moreover, bigger batch sizes up to 100 kg can now be handled by Ardena. Syntagon also adds specialist expertise in GMP chromatographic purification processes to the group.

The announcement follows Ardena’s acquisition of ChemConnection in March 2018 and is part of its strategy to form a leading integrated drug development company and reach the €35m sales mark this year.

Harry Christiaens, CEO of Ardena, comments: “At Ardena, it is our goal to become a one source contractor by offering an integrated set of services to meet all chemical, pharmaceutical and (bio)analytical needs that arise in the clinical supply chain from lab to patient. This is the driver of our M&A strategy.”

“By adding the ChemConnection and Syntagon capabilities to our group, we can now offer specialist technology expertise in drug substance manufacturing.”

Established in 1999, Syntagon has sites in Sweden and Latvia and employs 30 people. This latest acquisition brings the total number of Ardena facilities to six, including its headquarters in Ghent, Belgium and three sites in the Netherlands (Oss, Amsterdam and Assen).

Harry continued: “The Syntagon acquisition gives us a presence in Scandinavia, where we are well positioned to capitalize on the emerging biotech segment and broader pharmaceutical market. With support from our financial investor Mentha Capital, we will continue to focus on both organic growth and acquisition opportunities on our path to create an internationally recognized drug development company.”

Commenting on the acquisition, Michael Lofthagen, CEO at Syntagon added: “Our customers can now benefit from a more integrated service offering, which will ultimately streamline the progress of products through clinical development. We are looking forward to leveraging the synergies across the Ardena group to deliver the best possible offering to the market.”

Ardena was formed in 2017, following the merging of three companies with complementary capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands. With the acquisitions of ChemConnection and Syntagon in 2018, Ardena now employs more than 225 scientists.

Categories: News